OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biopharmaceutical company focused on antibody discovery technologies, having completed its de-SPAC business combination in 2022 through a merger with Avista Public Acquisition Corp. II, a blank-check company sponsored by Avista Capital Partners. The company was originally spun out of Ligand Pharmaceuticals and operates proprietary transgenic animal platforms designed to generate diverse antibody repertoires for partner drug discovery programs across the life sciences sector. OmniAb filed an 8-K current report with the SEC on June 21, 2024, under accession number 0001846253-24-000045, and remains publicly listed on Nasdaq following the close of its SPAC transaction. Sign up for SpacDesk to access full filing histories, deal timelines, and analytics on OmniAb and hundreds of other SPAC transactions.